MXPA05008583A - Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. - Google Patents
Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.Info
- Publication number
- MXPA05008583A MXPA05008583A MXPA05008583A MXPA05008583A MXPA05008583A MX PA05008583 A MXPA05008583 A MX PA05008583A MX PA05008583 A MXPA05008583 A MX PA05008583A MX PA05008583 A MXPA05008583 A MX PA05008583A MX PA05008583 A MXPA05008583 A MX PA05008583A
- Authority
- MX
- Mexico
- Prior art keywords
- cpt
- combination
- administration
- human
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Abstract
La presente invencion se refiere a un metodo para la produccion de un efecto antiangiogenico y/o de reduccion de permeabilidad vascular en un animal de sangre caliente tal como un ser humano, el cual opcionalmente esta siendo tratado con radiacion ionizante, en particular un metodo para el tratamiento de un cancer, particularmente un cancer que involucra un tumor solido, el cual comprende uno de: la administracion de ZD6474 en combinacion con 5-FU; la administracion de ZD6474 en combinacion con CPT-11; y la administracion de ZD6474 en combinacion con 5-FU y CPT-11; a una composicion farmaceutica que comprende uno de: ZD6474 y 5-FU; ZD6474 y CPT-11; y ZD6474 y CPT-11; a un producto de combinacion que comprende uno de ZD6474 y 5-FU; ZD6474 y CPT-11; y ZD6474 y 5-FU y CPT-11, para utilizarse en un metodo de tratamiento del cuerpo de un ser humano o animal a traves de terapia; a un cuerpo que comprende uno de: ZD6474 y 5-FU; ZD6474 y CPT-11; y ZD6474 y 5-FU y CPT-11; al uso de uno de ZD6474 y 5-FU; ZD6474 y CPT-11; y ZD6474 y 5-FU y CPT-11, en la fabricacion de un medicamento para utilizarse en la produccion de un efecto antiangiogenico y/o de reduccion de permeabilidad vascular en un animal de sangre caliente tal como un ser humano, el cual opcionalmente esta siendo tratado con radiacion ionizante.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0303289A GB0303289D0 (en) | 2003-02-13 | 2003-02-13 | Combination therapy |
| GB0314100A GB0314100D0 (en) | 2003-06-18 | 2003-06-18 | Combination therapy |
| GB0316184A GB0316184D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
| GB0318311A GB0318311D0 (en) | 2003-08-05 | 2003-08-05 | Combination therapy |
| PCT/GB2004/000550 WO2004071397A2 (en) | 2003-02-13 | 2004-02-11 | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008583A true MXPA05008583A (es) | 2005-11-04 |
Family
ID=32872851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008583A MXPA05008583A (es) | 2003-02-13 | 2004-02-11 | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20060142316A1 (es) |
| EP (1) | EP1592423B1 (es) |
| JP (3) | JP2006517575A (es) |
| KR (2) | KR20110006699A (es) |
| AT (1) | ATE506062T1 (es) |
| AU (1) | AU2004212255B2 (es) |
| CA (1) | CA2514227C (es) |
| CY (1) | CY1111565T1 (es) |
| DE (1) | DE602004032310D1 (es) |
| DK (1) | DK1592423T3 (es) |
| HK (1) | HK1084032A1 (es) |
| IL (1) | IL169702A (es) |
| MX (1) | MXPA05008583A (es) |
| NO (1) | NO331486B1 (es) |
| NZ (1) | NZ541297A (es) |
| PT (1) | PT1592423E (es) |
| SI (1) | SI1592423T1 (es) |
| WO (1) | WO2004071397A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| JP2006517575A (ja) * | 2003-02-13 | 2006-07-27 | アストラゼネカ アクチボラグ | 組合せ療法 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| DE602004028834D1 (de) * | 2003-07-10 | 2010-10-07 | Astrazeneca Ab | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
| WO2005117980A1 (en) * | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72946C2 (uk) * | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| CA2495487A1 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| JP2006517575A (ja) * | 2003-02-13 | 2006-07-27 | アストラゼネカ アクチボラグ | 組合せ療法 |
| DE602004028834D1 (de) * | 2003-07-10 | 2010-10-07 | Astrazeneca Ab | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| JP4834985B2 (ja) * | 2004-12-10 | 2011-12-14 | 日産自動車株式会社 | 組電池の容量調整装置 |
| JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
-
2004
- 2004-02-11 JP JP2006502268A patent/JP2006517575A/ja not_active Withdrawn
- 2004-02-11 PT PT04710081T patent/PT1592423E/pt unknown
- 2004-02-11 CA CA2514227A patent/CA2514227C/en not_active Expired - Fee Related
- 2004-02-11 MX MXPA05008583A patent/MXPA05008583A/es active IP Right Grant
- 2004-02-11 AT AT04710081T patent/ATE506062T1/de active
- 2004-02-11 DK DK04710081.3T patent/DK1592423T3/da active
- 2004-02-11 DE DE602004032310T patent/DE602004032310D1/de not_active Expired - Lifetime
- 2004-02-11 AU AU2004212255A patent/AU2004212255B2/en not_active Ceased
- 2004-02-11 KR KR1020107027024A patent/KR20110006699A/ko not_active Application Discontinuation
- 2004-02-11 KR KR1020057014913A patent/KR20050100683A/ko active Search and Examination
- 2004-02-11 US US10/543,106 patent/US20060142316A1/en not_active Abandoned
- 2004-02-11 EP EP04710081A patent/EP1592423B1/en not_active Expired - Lifetime
- 2004-02-11 NZ NZ541297A patent/NZ541297A/en not_active IP Right Cessation
- 2004-02-11 WO PCT/GB2004/000550 patent/WO2004071397A2/en active IP Right Grant
- 2004-02-11 SI SI200431690T patent/SI1592423T1/sl unknown
-
2005
- 2005-07-17 IL IL169702A patent/IL169702A/en not_active IP Right Cessation
- 2005-07-27 NO NO20053649A patent/NO331486B1/no not_active IP Right Cessation
-
2006
- 2006-04-11 HK HK06104405.5A patent/HK1084032A1/xx not_active IP Right Cessation
-
2009
- 2009-07-13 US US12/501,599 patent/US20100130520A1/en not_active Abandoned
-
2010
- 2010-10-25 JP JP2010238996A patent/JP5563950B2/ja not_active Expired - Fee Related
- 2010-12-20 US US12/973,271 patent/US20110086870A1/en not_active Abandoned
-
2011
- 2011-06-15 CY CY20111100565T patent/CY1111565T1/el unknown
- 2011-10-27 US US13/282,750 patent/US20120252826A1/en not_active Abandoned
-
2014
- 2014-01-23 JP JP2014010618A patent/JP2014065750A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110006699A (ko) | 2011-01-20 |
| JP2011016853A (ja) | 2011-01-27 |
| CA2514227A1 (en) | 2004-08-26 |
| PT1592423E (pt) | 2011-06-16 |
| DK1592423T3 (da) | 2011-06-27 |
| NO331486B1 (no) | 2012-01-16 |
| AU2004212255A1 (en) | 2004-08-26 |
| NO20053649D0 (no) | 2005-07-27 |
| JP2006517575A (ja) | 2006-07-27 |
| KR20050100683A (ko) | 2005-10-19 |
| JP5563950B2 (ja) | 2014-07-30 |
| HK1084032A1 (en) | 2006-07-21 |
| EP1592423B1 (en) | 2011-04-20 |
| IL169702A (en) | 2014-05-28 |
| EP1592423A2 (en) | 2005-11-09 |
| WO2004071397A2 (en) | 2004-08-26 |
| NO20053649L (no) | 2005-09-12 |
| US20110086870A1 (en) | 2011-04-14 |
| CA2514227C (en) | 2011-08-09 |
| WO2004071397A3 (en) | 2004-10-14 |
| CY1111565T1 (el) | 2015-10-07 |
| US20100130520A1 (en) | 2010-05-27 |
| SI1592423T1 (sl) | 2011-07-29 |
| ATE506062T1 (de) | 2011-05-15 |
| IL169702A0 (en) | 2007-07-04 |
| US20120252826A1 (en) | 2012-10-04 |
| AU2004212255B2 (en) | 2007-07-05 |
| US20060142316A1 (en) | 2006-06-29 |
| DE602004032310D1 (de) | 2011-06-01 |
| JP2014065750A (ja) | 2014-04-17 |
| NZ541297A (en) | 2008-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| IL169702A0 (en) | Combination therapy of zd6474 with 5-fu or/and cpt-11 | |
| MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
| HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
| ZA200600188B (en) | Combination therapy | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
| IL177953A0 (en) | Combination therapy including azd2171 and a taxane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |